Trisomy 12 in chronic lymphocytic leukemia--geographical variation

Area of Science:

• Hematology
• Cytogenetics
• Oncology

Background:

• Chronic lymphocytic leukemia (CLL) is a heterogeneous B-cell malignancy.
• Chromosomal abnormalities play a crucial role in CLL pathogenesis and prognosis.
• Trisomy 12 is a known cytogenetic aberration in CLL, but its precise incidence and clinical significance require further investigation.

Purpose of the Study:

• To determine the incidence of trisomy 12 in a cohort of CLL patients.
• To investigate the correlation between trisomy 12 and clinical parameters such as white blood cell (WBC) count and disease risk.
• To explore the relationship between trisomy 12 and immunophenotypic markers (FMC7, CD23) in CLL.

Main Methods:

• Fluorescence in situ hybridization (FISH) using a chromosome 12 specific alpha-satellite DNA probe.
• Analysis of 60 chronic lymphocytic leukemia (CLL) cases.
• Assessment of white blood cell (WBC) counts and immunophenotypic markers (FMC7, CD23).

Main Results:

• Trisomy 12 was detected in 37 (61.8%) of the 60 CLL patients.
• The proportion of trisomy 12 positive cells varied significantly (2% to 86%).
• Trisomy 12 was significantly associated with higher WBC counts (> 80 x 10(9) l(-1)) (P < 0.001) and high-risk disease groups (P < 0.05).
• No significant correlation was found between trisomy 12 positivity and FMC7 or CD23 expression.

Conclusions:

• Trisomy 12 is a frequent finding in chronic lymphocytic leukemia (CLL), particularly in patients with high white blood cell counts and advanced disease.
• The study suggests potential biological differences in CLL observed at their center compared to Western populations.
• Further research is warranted to elucidate the prognostic implications of trisomy 12 in diverse CLL patient groups.